Utility of the 70-gene MammaPrint assay for prediction of benefit from extended letrozole therapy (ELT) in the NRG Oncology/NSABP B-42 trial.

Priya Rastogi,Hanna Bandos,Peter C. Lucas,Laura van 't Veer,Jia-Perng Jennifer Wei,Charles E. Geyer,Louis Fehrenbacher,Mark L. Graham,Stephen Chia,Adam Brufsky,Janice M. Walshe,Gamini S. Soori,Shaker R. Dakhil,Soonmyung Paik,Sandra M. Swain,Andrea Menicucci,Shiyu Wang,M. William Audeh,Norman Wolmark,Eleftherios P. Mamounas

Utility of the 70-gene MammaPrint assay for prediction of benefit from extended letrozole therapy (ELT) in the NRG Oncology/NSABP B-42 trial.

2021

502Background: The 70-gene MammaPrint (MP) assay predicts risk of distant recurrence (DR) in hormone-receptor positive early-stage breast cancer and classifies cancers as Low Risk or High Risk. NSA...

Keywords:

Medicine
Letrozole
distant recurrence
Internal medicine
Oncology
Breast cancer
MammaPrint
Gene

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations